AstraZeneca-Oxfordās Covid-19 vaccine demonstrated an efficacy of 79% at preventing symptomatic Covid-19 in large-scale phase III trials in the US, much higher than UK trial results. Interim data rests speculation on the vaccineās efficacy on those over 65 years, and showed a 100% efficacy against severe disease & hospitalisation. The data validates it āas a much-needed additional vaccination option, offering confidence that adults of all ages can benefit fromĀ protection against the virusā, AstraZeneca said. Confidence in the safety of AstraZenecaās Covid-19 vaccine has taken a big hit in several countries in Europe as reports ofĀ rare blood clots have been linked to it,Ā with many countries temporarily pausing on its use in the vaccinations. In India, government is monitoring the serious adverse effects of the vaccines being administered, including Covishield, AstraZenecaās vaccine manufactured by Serum Institute. Meanwhile, India on March 22Ā said that the gap between the first and second doses of theĀ AstraZeneca-Oxford University's Covishield vaccine should be increased to 6-8 weeks from the current 28 days.
Google Trends